Drug
BMS 708163 clinical trials
Also written BMS-708163.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Galantamine (1) · Rifampin (1) · Donepezil (1) · Ketoconazole (1) · Fluconazole (1)
Studies
Open first, then newest update. How each study uses BMS 708163 is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2Bristol-Myers SquibbNCT00810147Written as BMS-708163
- A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's DiseaseTerminatedPhase 2Bristol-Myers SquibbNCT00890890Written as Avagacestat
- Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163CompletedPhase 1Bristol-Myers SquibbNCT01454115Written as BMS-708163 (Gamma-Secretase Inhibitor)
- Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163CompletedPhase 1Bristol-Myers SquibbNCT01079819Written as BMS-708163
- Multiple Dose Japanese Bridging StudyCompletedPhase 1Bristol-Myers SquibbNCT01057030Written as BMS-708163
- Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)CompletedPhase 1Bristol-Myers SquibbNCT01039194Written as BMS-708163
- Drug-Drug Interaction Study With RifampinCompletedPhase 1Bristol-Myers SquibbNCT01002079Written as BMS-708163
- Drug-Drug Interaction Study With Aricept® (Donepezil)CompletedPhase 1Bristol-Myers SquibbNCT01042314Written as BMS-708163
- Drug-Drug Interaction (DDI) w/Ketoconazole or FluconazoleCompletedPhase 1Bristol-Myers SquibbNCT00860275Written as BMS-708163
- Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT00979316Written as BMS-708163
- Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly JapaneseCompletedPhase 1Bristol-Myers SquibbNCT00828646Written as BMS-708163
- Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseCompletedPhase 1Bristol-Myers SquibbNCT00901498Written as BMS-708163
- Drug Interaction Study With a Potential Alzheimer's Disease CompoundCompletedPhase 1Bristol-Myers SquibbNCT00726726Written as BMS-708163
Codes
What other systems call BMS 708163 · ClinicalTrials.gg INT005747
- MeSH (NLM) C554092BMS 708163One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C554092 | BMS 708163 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.